Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Source: Yahoo Finance
Financial Performance: Cosmo Pharmaceuticals reported strong half-year results for 2025, raising its EBITDA guidance by €4.5 million and achieving a 128% increase in recurring revenues from GI Genius™ and a 23% increase from Winlevi®.
Strategic Outlook: The company anticipates continued growth in the second half of 2025, with expectations of €43-48 million in recurring revenues and increased R&D spending to advance key programs, while maintaining cost discipline and operational efficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
